开发一种新的患者报告的杜普伊特伦病结局指标:研究协议
David Eckerdal1,2, Per-Erik Lyrén3, Jane McEachan4
1Department of Orthopedics, Hässleholm-Kristianstad Hospitals, Hässleholm, Sweden.
Health informatics journal
|November 15, 2024
概括
本研究开发了一种新的杜普伊特伦病患者报告结果测量方法 (PROM),使用物品反应理论 (IRT) 来改善对手指收缩治疗结果的评估.
科学领域:
- 整形外科 整形外科 整形外科
- 类风湿病学 类风湿病学
- 健康 结果 研究 研究 结果
背景情况:
- 杜普伊特伦病导致手指逐渐收缩,损害手的功能和日常活动.
- 对于杜普伊特伦病,目前患者报告的结果指标 (PROM) 往往缺乏响应性和项目相关性.
- 传统的PROM开发方法可能无法完全捕捉疾病的影响.
研究的目的:
- 开发一种新的Dupuytren特定PROM,使用现代物品响应理论 (IRT) 方法.
- 加强对杜普伊特伦病治疗有效性的评估.
- 为临床研究和实践创造一个更具响应性和相关的结果衡量标准.
主要方法:
- 这是一项三阶段研究,涉及专家组,患者合作和问卷开发.
- 将物品反应理论 (IRT) 分析应用于300名杜普伊特伦病患者的数据 (第二阶段).
- 在300名杜普伊特伦病患者的独立队列中验证新的PROM (第三阶段).
主要成果:
- 第1阶段通过专家和患者的投入成功生成了全面的项目库.
- 第二阶段的IRT分析将确定新PROM的最佳项目.
- 第三阶段将确认开发的Dupuytren特异性PROM的有效性和可靠性.
结论:
- 基于IRT开发的Dupuytren特异性PROM预计将改善临床研究.
- 这项新措施将为评估干预提供更准确,更快速的工具.
- 通过改善结果测量,促进对杜普伊特伦病的理解和管理.
更多相关视频
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
10.3K
08:48Author Spotlight: Exploring the Complexities of Achilles Tendon Injuries — Research and Future Directions
Published on: October 27, 2023
642
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...